Dracocephalum moldavica Compound for Heart Injury
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
The European Patent Office published application EP3228316A1 for Nanjing Ruiying Runze Biopharmaceutical Technology Co., Inc. covering a composition containing active components of Dracocephalum moldavica L. for treating myocardial ischemia-reperfusion injury. The patent application includes IPC classifications A61K 31/7048, A61P 9/10, and A61P 9/06, designating all EU member states and extension states.
What changed
The EPO published a patent application (EP3228316A1) for a pharmaceutical composition derived from Dracocephalum moldavica L. The invention claims active components for therapeutic use against myocardial ischemia-reperfusion injury, with six listed inventors and designation extended to 34 EU and extension states including DE, FR, GB, IT, ES, and others.\n\nThis is a patent publication notice with no compliance obligations for third parties. Pharmaceutical companies and researchers developing cardiovascular treatments may wish to review for freedom-to-operate considerations. No deadlines, fees, or regulatory responses are required from industry participants.
Source document (simplified)
COMPOSITION CONTAINING ACTIVE COMPONENTS OF DRACOCEPHALUM MOLDAVICA L. AGAINST MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
Publication EP3228316A1 Kind: A1 Mar 25, 2026
Applicants
Nanjing Ruiying Runze Biopharmaceutical
Technology Co., Inc.
Inventors
SHANG, Jing, YU, Dongsheng, TIAN, Youqing, WU, Huali, DING, Lin, LIU, Jun
IPC Classifications
A61K 31/7048 20060101AFI20250602BHEP A61P 9/10 20060101ALI20250602BHEP A61K 31/352 20060101ALI20250602BHEP A61P 9/06 20060101ALI20250602BHEP A61K 36/53 20060101ALI20250602BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.